tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta Shareholders Approve 2026 Equity and ESPP Plans
Company AnnouncementsSarepta Shareholders Approve 2026 Equity and ESPP Plans
7d ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
7d ago
AZN
BMY
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
PremiumCompany Announcements
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
7d ago
SRPT
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
9d ago
AZN
BMY
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
PremiumRatings
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
27d ago
SRPT
Sarepta price target lowered to $19 from $20 at Evercore ISI
PremiumThe FlySarepta price target lowered to $19 from $20 at Evercore ISI
27d ago
SRPT
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
30d ago
AZN
BMY
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
Premium
The Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
1M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
1M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
1M ago
DYN
RNA
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
PremiumRatings
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
1M ago
SRPT
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
PremiumRatings
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
1M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
PremiumRatingsGil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
1M ago
SRPT
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
Premium
Ratings
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
1M ago
SRPT
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
Premium
Ratings
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
1M ago
SRPT
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
PremiumThe Fly
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
1M ago
SRPT
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
PremiumCompany Announcements
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
1M ago
SRPT
SRPT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SRPT Upcoming Earnings Report: What to Expect?
1M ago
SRPT
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
PremiumThe Fly
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
2M ago
BA
BE
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
PremiumThe FlyRoche decision could hurt Sarepta in U.S., says H.C. Wainwright
2M ago
CHRO
SRPT
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
Premium
The Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
2M ago
DYN
RNA
Sarepta price target raised to $19 from $18 at RBC Capital
Premium
The Fly
Sarepta price target raised to $19 from $18 at RBC Capital
2M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >